✦ LIBER ✦

Optimising immunotherapy for malignant melanoma

Book ID: 120867911
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 176 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012620-00017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunotherapy of malignant melanoma

✍ Thiers, Bruce H. 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 423 KB

Immunotherapy of malignant melanoma

✍ Kadison, Alan S; Morton, Donald L 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 343 KB

BCG immunotherapy for recurrent malignan

BCG immunotherapy for recurrent malignant melanoma

✍ Shelley L. Rasmussen; Jordan U. Gutterman; Evan M. Hersh; Sydney Boston; M. Mars 📂 Article 📅 1980 🏛 Springer-Verlag 🌐 English ⚖ 789 KB

A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of

Experimental trials of immunotherapy for

Experimental trials of immunotherapy for malignant melanoma

✍ Douglas Reintgen; Jeanne Becker; Hilliard F. Seigler 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Conventional treatment for metastatic melanoma consists of surgical resection, chemotherapy, and radiation therapy. New approaches toward treatment of this disease include the development of passive and active immunotherapeutic regimens. Malignant melanoma is particularly amendable to immunotherapy

Adjuvant immunotherapy of malignant mela

Adjuvant immunotherapy of malignant melanoma

✍ Gerard V. Aranha; Charles F. McKhann; Theodor B. Grage; Audolfur Gunnarsson; Ric 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

Immunotherapy for malignant melanoma: A

Immunotherapy for malignant melanoma: A review and update

✍ J. Michael C. Mcgee 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

Several different approaches to the application of specific active immunotherapy for the adjuvant therapy of melanoma have developed independently. Specific active immunotherapy refers to autologous or allogenic inoculation or transplantation of tumor cells or cell products into patients with cancer